
News|Articles|October 1, 2006
High-dose statin therapy displays benefit in preventing cardiovascular events compared with standard doses
Intensive lipid lowering with high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) provides a significant benefit over standard-dose statin therapy in preventing nonfatal cardiovascular outcomes and also may reduce the incidence of cardiovascular death, according to results of a meta-analysis published in the Journal of the American College of Cardiology.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Predictions for 2026 from Lucille Accetta, RPh, M.P.H., MBA, A.J. Loiacono and Allan Pannier, Pharm.D. MBA
2
FDA issues third rejection of bevacizumab to treat wet AMD
3
Top 5 articles from the MHE print publication
4
Predictions for 2026 from Tracy Baroni Allmon, Sharon Faust, Mike Kolodij, and others
5




















































